Objective To evaluate the health related quality of life (HRQOL) of patients with chronic hepatitis C(CHC) and the improvement after interferon therapy. Methods Using the SF 36 questionnaire and the hepatitis specific scale derived from the Medical Outcomes Study (MOS), the HRQOL in 67 non cirrhotic patients with chronic HCV infection were evaluated, 38 patients of which were treated with IFN ?2a 3MU( n=31) and CIFN 15 ?g ( n =7), three times a week for 6 months. 12 patients had a sustained viral response (undetectable serum HCV RNA and normal ALT level at 24 weeks post treatment) to interferon therapy. 26 patients had no response. Live biopsies were performed in 23 patients and the diagnosis of chronic hepatitis proved. These scales were self administered by patients at baseline and at 24 weeks post treatment. Patients with chronic hepatitis C were compared with healthy volunteers ( n =40) who were selected as normal controls, the age, sex, education profession were matched between them. Results Compared with healthy controls, patients with chronic hepatitis C at baseline had lower HRQOL on all eight scales of the SF 36 ( P

Eukaryotic DNA replication is tightly restricted to only once per cell cycle in order to maintain genome stability. Cells use multiple mechanisms to control the assembly of the prereplication complex (pre-RC), a process known as replication licensing. This review focuses on the regulation of replication licensing by posttranslational modifications of the licensing factors, including phosphorylation, ubiquitylation and acetylation. These modifications are critical in establishing the pre-RC complexes as well as preventing rereplication in each cell cycle. The relationship between rereplication and diseases, including cancer and virus infection, is discussed as well.
Acetylation ; Animals ; Cell Cycle ; DNA Replication ; genetics ; physiology ; DNA Replication Timing ; DNA, Neoplasm ; biosynthesis ; genetics ; Genomic Instability ; Host-Pathogen Interactions ; Humans ; Models, Biological ; Neoplasms ; drug therapy ; genetics ; metabolism ; Phosphorylation ; Protein Processing, Post-Translational ; Ubiquitination ; Virus Diseases ; genetics ; metabolism